by Eric Christianson | Dec 17, 2023 | Endocrine Medication and Disease State Clinical Pearls
Semaglutide products have been popping up in news headlines recently, and not because of their continued popularity as effective weight loss medications. Data from poison control centers across the country indicates a drastic increase over the past year in calls...
by Eric Christianson | Nov 15, 2023 | Gastrointestinal Medication and Disease State Clinical Pearls
This article is going to compare Wegovy versus Ozempic, two different brand-name medications that share the same active ingredient: semaglutide. Both medications are subcutaneous injections, and both are administered once per week using pen injector devices. The...
by Eric Christianson | Mar 3, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Obesity is a major risk factor for many comorbidities (hypertension, dyslipidemia, osteoarthritis, sleep apnea, heart disease, type 2 diabetes) and increases all-cause and cardiovascular mortality. With over 40% of Americans qualifying as obese (body mass index ≥30...
by Eric Christianson | Jan 26, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
I recently received a text from a friend about the use of oral semaglutide in a patient with diabetes. It is definitely exciting to have more options for patients, even though we know there will inevitably be insurance coverage hurdles to jump through. Here are a few...
by Eric Christianson | Sep 25, 2019 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
The author has no conflicts of interest regarding oral semaglutide or any other diabetes medication. The GLP-1 agonists have been growing in popularity. The benefit of good A1C lowering effect coupled with the potential for weight loss are two of the main reasons why...
